Columbus Venture Partners

MANAGEMENT TEAM

Javier García
General Partner

Damià Tormo
General Partner

Julen Oyarzabal
Partner

Marc Marco
Partner

Eva Rodrigo
Chief Financial Officer

Tino Balestra
Senior Finance Analyst

Ana Elcarte
Executive Assistant and Corporate Communications

Cristina Andrés
Executive Assistant and Head of Administration

Beatriz Galbis
Head of Legal

Carlos Lloris
Finance & Operations Support Team

Ana Gonzalez
Finance & Operations Support Team

Guillermo Ribes
Operational Partner

Jose Vicente Pons
Operational Partner

Raj Parekh
Fund Advisor

Robert Armstrong
Fund Advisor

COLUMBUS INNVIERTE LIFE SCIENCE

Columbus Venture Partners’ investment strategy is focused on early-stage and high growth opportunities of biotechnology, medical technology, pharmaceuticals and healthcare industries.

We have analyzed in detail the Spanish biotechnology sector, and have contrasted the opportunities for private investors, other venture capital funds, and pharmaceutical and biotechnology companies. Our conclusion is there is a huge opportunity to develop ideas and to transfer out advance technology of Universities and Research Centers into market driven companies.

THE EFFICIENT FRONTIER: A DIVERSIFIED PORTFOLIO WITH OPTIMIZED RISK – RETURN. WELL KNOWN MODERN PORTOFOLIOS THEORY AT ITS BEST

SEARCH

● Search of deal flow in Research Centers and early stage assets from existing companies.

● Collaboration agreements with TLOs.

TECHNOLOGY VALIDATION

● Assestment market needs.

● IP Position.

● Commercial Viability.

● Resources needed, timelines and milestones.

INCUBATION

● Business Plan.

● Scientific/Tech validation.

● Management.

● Networking.

ACCELERATION

● Project Development.

● Team.

● International.

● SAB/BoD.

HOPE ACCELERATES HERE

At Columbus Venture Partners we believe that innovation has a real impact on society and, in particular, on those with the greatest needs. However, pharmaceutical developments focus on indications or diseases that, due to the number of patients, have a positive economic return potential on the executed investment. Therefore, ultra-rare disease treatments are often hampered not for technical reasons but for cost-effectiveness. For that reason, our goal from Columbus is to bring these cutting-edge innovations forward so that research and development of treatments for these ultra-rare diseases advance at the same rate as other larger indications. Children with these diseases and their families need an urgently access to these transformative medicines. Most of them suffer from a severely altered lifestyle, and in many cases life expectancy is less than ten years. At Columbus Venture Partners we are deeply motivated by the urgent needs to ensure that no child is left behind. Thus, we work with the Columbus Foundation (Spain) and the Columbus Children Foundation (USA) in collaboration with Askbio and Viralgen to provide a solution to these diseases.

You can follow our activity at the Columbus Foundation (Spain) and the Columbus Children Foundation (USA).

IMPROVED INVESTMENT STRATEGY LEVERAGES RETURN

High value with alternative and attractive risk/reward profiles, commercially and scientifically differentiated.

Lean structure, cost efficient, accessible shared resources, access to low-cost incubator.

Hands-on investments. Founder ROI in investments: leverages return. Board role in 100% of the investments in the portfolio.

Projects co-invested or partnered with global VC firms and Top pharmaceutical companies. Preferred access to novel technologies.

An efficient frontier: a diversified portfolio with optimized risk-return. Please visit https://columbusvp.com/portfolio-columbusvp/ for further details